RTT Premium Stocks

Home
United States
Washington D.C., DC
RTT Premium Stocks

RTT Biotech Investor and RTT Intelligent Investor services give subscribers the edge to make more successful investments. Welcome to RTTNews Premium stocks.

For over 20 years, RTTNews has been providing news and analysis from around the globe that can impact individual stocks and broader markets to leading banks, brokerages and hedge funds. Now RTT is offering the same information to individual investors and traders. RTT Premium Stocks consists of RTT Biotech Investor and RTT Intelligent Investor

RTT Biotech Investor - Biotech investment is one of the exciting spaces in the stock market. The companies in this sector focus on clinical research and development of new drugs. There is tremendous potential for stocks to deliver outstanding gains when companies report positive trial data or when their drugs obtain FDA approval. At RTTNews, a dedicated team tracks these companies and developments. As a subscriber, you will have access to all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions. RTT Intelligent Investor - is your all-encompassing guide to profitable investment decisions. The daily newsletter filters through though mounds of data to provide timely and valuable information to subscribers. Our premium alerts identify stocks with upside potential, handpicked after meticulous research and analysis to help you benefit from the stock market in the next few days/weeks/months. Our premium services give subscribers the edge they need to make more successful investments and trades by discovering opportunities long before they catch the attention of mainstream investors. Our stocks have consistently and significantly outperformed the broader markets. Unlike other services that highlight a few top gainers, we provide a complete performance table for all the stocks we publish, so you can see the true performance of the service at any given time. By incorporating our research into your trading strategy, you can find the best trading opportunities every day. Let our experts provide you with timely insight and analysis, so you can focus on your investment strategies. Along with our in-depth research and concise reports, we also provide technical analysis that identify key support/resistance levels, stock trends, chart patterns and other key indicators when applicable. Sign up today for your RISK-FREE 7 day trial, and let us help you find the best investment and trading opportunities.

01/09/2025

𝗙𝗿𝗼𝗺 𝗔𝗹𝗲𝗿𝘁 𝘁𝗼 𝗔𝗹𝗹-𝗧𝗶𝗺𝗲 𝗛𝗶𝗴𝗵: 𝗔𝗠𝗦𝗖'𝘀 𝟳𝟰.𝟰% 𝗝𝘂𝗺𝗽 𝗶𝗻 𝟯𝟴 𝗗𝗮𝘆𝘀

We alerted our premium subscribers to American Superconductor Corp. (AMSC) stock on September 20, 2024, when it was trading at around $21.80. By November 13, 2024, this power technologies stock reached an all-time high of $38.02, marking an impressive 74.4% increase from our published price.

Click Below 👇 to Subscribe to RTT Intelligent Investor & read this report

https://bit.ly/30kAY7q

‘Intelligent Investor’ is your all-encompassing guide to profitable investment decisions. The daily newsletter filters through mounds of data to provide timely and valuable information to subscribers. Our premium alerts identify stocks with upside po

06/05/2024

𝗗𝗶𝗱 𝗬𝗼𝘂 𝗣𝗶𝗰𝗸 𝗨𝗽 𝗣𝗜 𝗕𝗲𝗳𝗼𝗿𝗲 𝗜𝘁 𝗚𝗮𝗶𝗻𝗲𝗱 𝟴𝟵%?

RFID maker Impinj Inc. (PI), was featured on our 'Short-Term Investor' on January 17, 2024, when it was trading at around $92.45. On May 16, 2024, the stock reached an all-time high of $175.41, representing a gain of 89.7% from our published price.

Click Below 👇 to Subscribe to RTT Intelligent Investor & read this report

https://bit.ly/30kAY7q

05/20/2024

𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗦𝘁𝗼𝗰𝗸 𝘄𝗶𝘁𝗵 𝟰𝟴.𝟴% 𝗥𝗲𝘁𝘂𝗿𝗻 𝗶𝗻 𝗝𝘂𝘀𝘁 𝟯𝟲 𝗗𝗮𝘆𝘀 - 𝗗𝗼 𝗬𝗼𝘂 𝗢𝘄𝗻?

We alerted our premium subscribers to NovoCure Ltd. (NVCR) stock on March 27, 2024, when it was trading at around $14.99. Subsequently, on May 17, 2024, this oncology stock reached an intra-day high of $22.31, signifying a notable increase of 48.8% from our published price.

Click Below 👇 to Subscribe to RTT Intelligent Investor & read this report

https://bit.ly/30kAY7q

05/13/2024

𝗔𝗳𝘁𝗲𝗿 𝗶𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀, 𝗔𝗗𝗠𝗔 𝗦𝗲𝘁𝘀 𝘁𝗵𝗲 𝗕𝗮𝗿 𝗛𝗶𝗴𝗵 𝗳𝗼𝗿 𝟮𝟬𝟮𝟰

ADMA Biologics, Inc. (ADMA), which delivered strong Q1 results, has revised up its guidance for 2024 again. On Feb.15, 2024, we featured ADMA on our site when it was trading around $5. The stock touched a 52-week high of $9.02 last week (May 10), before closing at $8.81.

Click Below 👇 to Subscribe to RTT Biotech Investor & read this report
https://bit.ly/3tAnX3T